MediLink Therapeutics (Suzhou) Co., Ltd.
MediLink Therapeutics (Suzhou) Co., Ltd.
Explore linked clinical trials.24 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 | 2026-09-18 | NCT06859762 | |
| A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-09-17 | NCT07407933 | |
| A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301) | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Active, not recruiting | Phase 3 | 2026-09-17 | NCT06629597 | |
| A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Active, not recruiting | Phase 3 | 2026-09-15 | NCT06612151 | |
| A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Not yet recruiting | Phase 3 | 2026-09-04 | NCT07803783 | |
| A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer | SCLC, Extensive Stage | Recruiting | Phase 3 | 2026-08-24 | NCT07739758 | |
| Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 | 2026-08-13 | NCT06384352 | |
| A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lethal congenital contracture syndrome 2, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-08-05 | NCT07111520 | |
| A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-07-17 | NCT06439771 | |
| A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy | Advanced Esophageal Squamous Cell Carcinoma | Recruiting | Phase 3 | 2026-07-16 | NCT07487896 | |
| A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors | Advanced Solid Tumors | Active, not recruiting | Phase 1 | 2026-06-25 | NCT06394414 | |
| A Study of YL201 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | Recruiting | Phase 1 / Phase 2 | 2026-06-22 | NCT05434234 | |
| A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-06-18 | NCT07208773 | |
| Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-06-15 | NCT07416994 | |
| YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-05-26 | NCT07461454 | |
| A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, breast cancer, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder | Active, not recruiting | Phase 1 | 2026-05-15 | NCT05653752 | |
| A Study YL201 in Patients With Selected Advanced Solid Tumors | Advanced Solid Tumor | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-12 | NCT06057922 | |
| A Study of YL202 in Patients With Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, bronchial neoplasm, bronchogenic carcinoma, cervix disorder, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, female reproductive system disorder, female reproductive system neoplasm, intestinal disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, rectal disorder, respiratory system disorder, respiratory tract neoplasm, uterine disorder | Recruiting | Phase 2 | 2026-03-09 | NCT07202364 | |
| A Study of YL242 in Subjects With Advanced Solid Tumors | neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-12-24 | NCT07197827 | |
| A Clinical Study of YL205 in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2025-12-23 | NCT06459973 | |
| A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. | Disease Attributes, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pharyngeal Diseases, Recurrence, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Phase 1 / Phase 2 | 2025-12-02 | NCT07258979 | |
| A Study of YL202 in Selected Patients With Advanced Solid Tumors | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, non-small cell lung carcinoma, skin disorder, squamous cell carcinoma | Recruiting | Phase 2 | 2025-11-26 | NCT06107686 | |
| A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, breast cancer, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder | Recruiting | Phase 1 / Phase 2 | 2025-09-12 | NCT07169994 | |
| A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Recruiting | Phase 2 | 2025-08-27 | NCT06241846 |